Trending

Adcetris

Scotland backs Roche’s Rozlytrek for ROS1 lung cancer

Scotland backs Roche’s Rozlytrek for ROS1 lung cancer

The Scottish Medicines Consortium (SMC) has given a green light to Roche’s Rozlytrek for a rare form of

X

Scotland backs Roche’s Rozlytrek for ROS1 lung cancer

https://pharmaphorum.com/news/scotland-backs-roches-rozlytrek-for-ntrk-tumours/

NICE backs NHS use of Takeda’s Adcetris for rare blood cancer

NICE backs NHS use of Takeda’s Adcetris for rare blood cancer

Takeda’s antibody-drug conjugate Adcetris can now be routinely available on the NHS to patients with a rare form

X

NICE backs NHS use of Takeda’s Adcetris for rare blood cancer

https://pharmaphorum.com/news/nice-backs-nhs-use-of-takedas-adcetris-for-rare-blood-cancer/

Adcetris falls victim to NICE’s Cancer Drugs Fund clear-out

Adcetris falls victim to NICE’s Cancer Drugs Fund clear-out

More CDF legacy products likely to face same fate

X

Adcetris falls victim to NICE’s Cancer Drugs Fund clear-out

https://pharmaphorum.com/news/adcetris-falls-victim-nices-cancer-drugs-fund-clear/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com